Adverum Biotechnologies (ADVM) has released an update to notify the public and investors about the unregistered sales of equity securities.
The company has conducted a private placement of securities relying on exemptions provided by Regulation D of the Securities Act of 1933 and state laws, avoiding the need for registration with the SEC. The securities are sold exclusively to accredited investors who intend to hold them for investment purposes, not for immediate resale. This move is not a public offering and eschews general solicitation and advertising. The company’s report also contains forward-looking statements projecting the completion and financial benefits of this private placement while acknowledging the risks and uncertainties inherent in such forward-looking projections.
For further insights into ADVM stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
